【摘要】 目的 :评价 TPT联合 DDP对初治 SCL C的疗效及其不良反应。方法 :5 0例 SCL C患者随机分为 2组 :A组 :TPT1mg/ m2 .d,静脉滴注 ,d1～ 5;DDP80 mg/ m2 ,静脉滴注 ,总量分为 3天使用 ,d1～ 3 。B组 :Vp- 16 10 0 mg/ d,静脉滴注 ,d1～ 5;DDP 80 mg/ m2 ,静脉滴注 ,总量分为 3天使用 ,d1～ 3 。 A、 B两组均为每 3周 1疗程。结果 :TPT联合 DDP初治 SCL C有效率 70 .8%(17/ 2 4) ,对照组的 EP方案有效率 76 .0 %(18/ 2 5 ) ,较 A组稍高 ,但统计学比较无差异。 A组 WBC下降 92 .0 %(其中 ～ 度下降者 5 2 .0 %) ,B组 WBC下降率与 A组相当 ,但 ～ 度下降者 12 .0 %,较 A组低 (P <0 .0 0 5 ) :A组PL T下降 40 .0 %(其中 ～ 度下降者 12 .0 %) ,B组 PL T下降较 A组低 ,为 12 .0 %(0 .0 2 5 >P >0 .0 1) ;A组 Hb下降40 .0 %与 B组 32 .0 %类似 (0 .5 <P <0 .75 )。显示 A组 WBC、 PL T较 B组下降率高且程度严重。结论 :TPT联合 DDP方案不宜作为 SCL C的一线方案 ,而应作为 SCL C复发后的二线治疗方案。更多还原

【Abstract】 Objective:To evaluate the effect and toxicity of topotecan (TPT) and cisplatin (DDP) combination as the first line chemotherapy in patients with small cell lung cancer (SCLC).Methods:A total of 50 patients were randomly assigned to Arm A:TPT 1mg/m 2/d,iv drop,d1~5;DDP 80mg/m2,iv drop,divided three doses for d1~3.Arm B:VP-16 100mg/d,iv drop,d1~5;DDP 80mg/m 2,iv drop,divided three doses for d1~3.Both regimens were repeated every 3 weeks.Results:The response rate in the Arm A was 70.8%(17/24),lower than that (76.0%,18/25) in the Arm B,no significant difference statistically.Myelosuppression was more frequent,however,in the Arm A:grade Ⅲ~Ⅳ neutropenia occurred in 52.0% vs.only 12.0% in the Arm B (P<0.005),and grade Ⅲ~Ⅳ thrombocytopenia was 12.0% vs.0%,respectively (P<0.025).Conclusion:The results suggested the topotecan and cisplatin combination should be the second line regimen,not the first line.更多还原